

# Calendar Update of the Annual General Meeting 2026

**Magle Group today announces that its Annual General Meeting is planned for 30 June 2026, following the previously announced delay to the publication of the Annual Report for the financial year 2025, now expected on 9 June 2026.**

Further information regarding the AGM, including formal notice and proposed agenda, will be published in due course in accordance with applicable rules and regulations.

## Contacts

---

Aaron Wong, Interim CEO, CFO, phone +46 (0)76 664 35 79, aaron.wong@maglegroup.com

## About Us

---

The Magle Group aims to establish itself as a leader in high-quality life-changing healthcare innovations to meet medical needs through scientific excellence. The Magle Group is founded on strategic acquisitions aimed at driving growth and diversifying risk. Today, the Group includes three operational areas. Magle Chemoswed – a contract development and manufacturing organization (CDMO) with a strong reputation for its high-quality development and manufacturing expertise and Magle PharmaCept – an established sales and marketing company for development and direct sales of the Groups medical technology products. Magle Biopolymers A/S- a specialized manufacturing organization of Dextran technology. Learn more on [www.maglechemoswed.com](http://www.maglechemoswed.com) and [www.maglegroup.com](http://www.maglegroup.com) and [www.maglepharmaceut.com](http://www.maglepharmaceut.com) and [www.maglebiopolymers.com](http://www.maglebiopolymers.com) Redeye Nordic Growth AB is the company's Certified Adviser.

## Attachments

---

[Calendar Update of the Annual General Meeting 2026](#)